Quintrio
Home

Stock overview

AgomAb Therapeutics NV American Depositary Shares

AGMB

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Last trade $5.91
Day change -$0.065 (-1.09%)
Day range $5.54 – $6.44
Volume 229,910
Market cap $294M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for AGMB.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for AGMB.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Agomab Announces Results of Annual General Meeting

Agomab Therapeutics NV held its Annual General Meeting on May 26, 2026, with all agenda items approved including financial statements for 2025 and board member reappointments. The company reported full year 2025 financial results and confirmed its 2026 outlook.

GlobeNewswire Inc.

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics reported €116.5 million in cash at year-end 2025 and raised $208 million in gross IPO proceeds in February 2026, extending cash runway into H1 2029. The company achieved positive Phase 2a results for ontunisertib in fibrostenosing Crohn's disease and positive Phase 1 results for AGMB-447 in healthy participants. Agomab is on track to initiate Phase 2b studies for both lead candidates in H2 2026, with topline data from extension and IPF cohort studies expected in the same period.

GlobeNewswire Inc.

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Therapeutics NV announced that the USPTO granted U.S. Patent No. 12,577,230 for AGMB-447, an investigational inhaled lung-restricted small molecule inhibitor of ALK5 for treating Idiopathic Pulmonary Fibrosis. The patent provides IP protection through at least 2041. The company is currently conducting a Phase 1b study and expects to report results from the IPF patient cohort later in 2026.

Benzinga

Agomab Announces Closing of Initial Public Offering

Agomab Therapeutics NV (NASDAQ: AGMB), a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for immunology and inflammatory diseases, announced the successful closing of its IPO on February 9, 2026. The company offered 12.5 million American Depositary Shares at $16.00 per share, raising approximately $200 million in gross proceeds. Trading began on the Nasdaq Global Select Market on February 6, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.